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Abstract
 Background—Although preterm birth less than 37 weeks gestation is the leading cause of 
neonatal morbidity and mortality in the United States, the majority of data regarding preterm 
neonatal outcomes come from older studies, and many reports have been limited to only very 
preterm neonates. Delineation of neonatal outcomes by delivery gestational age is needed to 
further clarify the continuum of mortality and morbidity frequencies among preterm neonates.
 Objective—We sought to describe the contemporary frequencies of neonatal death, neonatal 
morbidities, and neonatal length of stay across the spectrum of preterm gestational ages.
 Study Design—Secondary analysis of an obstetric cohort of 115,502 women and their 
neonates who were born in 25 hospitals nationwide, 2008–2011. All live born non-anomalous 
singleton preterm (23.0–36.9 weeks of gestation) neonates were included in this analysis. The 
frequency of neonatal death, major neonatal morbidity (intraventricular hemorrhage grade III/IV, 
seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stage II/III, 
bronchopulmonary dysplasia, persistent pulmonary hypertension), and minor neonatal morbidity 
(hypotension requiring treatment, intraventricular hemorrhage grade 1/2, necrotizing enterocolitis 
stage 1, respiratory distress syndrome, hyperbilirubinemia requiring treatment) were calculated by 
delivery gestational age; each neonate was classified once by the worst outcome they met criteria 
for.
 Results—8,334 deliveries met inclusion criteria. There were 119 neonatal deaths (1.4%). 657 
(7.9%) neonates had major morbidity, 3,136 (37.6%) had minor morbidity, and 4,422 (53.1%) 
survived without any of the studied morbidities. Deaths declined rapidly with each advancing 
week of gestation. This decline in death was accompanied by an increase in major neonatal 
morbidity, which peaked at 54.8% at 25 weeks of gestation. As frequencies of death, and major 
neonatal morbidity fell, minor neonatal morbidity increased, peaking at 81.7% at 31 weeks of 
gestation. The frequency of all morbidities fell beyond 32 weeks. Neonatal length of hospital stay 
decreased significantly with each additional completed week of pregnancy; among babies 
delivered from 26 to 32 weeks of gestation, each additional week in utero reduced the subsequent 
length of neonatal hospitalization by a minimum of 8 days. The median post-menstrual age at 
discharge nadired at 35.7 weeks post-menstrual age for babies born at 32–33 weeks of gestation.
 Conclusions—Our data show that there is a continuum of outcomes, with each additional 
week for gestation conferring survival benefit while reducing the length of initial hospitalization. 
These contemporary data can be useful for patient counseling regarding preterm outcomes.
Keywords
neonatal morbidity; neonatal mortality; prematurity
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 Introduction
Preterm delivery less than 37 weeks of gestation remains the leading cause of neonatal and 
childhood morbidity among non-anomalous infants in the United States and the developed 
world, and is the leading cause of death worldwide.1–3 Recent advances in perinatal and 
neonatal medicine have resulted in substantial improvements in outcomes among premature 
infants.4–6 A large study by the Neonatal Research Network found improvements in rates of 
death and major morbidity among neonates delivered at 23–24 weeks of gestation between 
2009–2012, after outcomes had been relatively static between 1993–2008.6 Despite this, 
rates of neonatal morbidity remain high, particularly among the most premature neonates. 
The majority of data regarding preterm neonatal death and morbidity come from older 
studies. Additionally, many studies have been limited to include only very preterm neonates, 
and frequently have focused on outcomes by birthweight cutoffs.4,7–9 Outcomes by 
birthweight may be skewed by inclusion of more mature neonates with growth restriction.4,8
Gestational age at delivery is one of the major determinants of neonatal survival and 
morbidity. Clinicians and researchers commonly classify women with PTB as delivering 
‘early preterm’ or ‘late preterm.’ ‘Early’ PTB is typically regarded as delivery prior to 32 or 
34 weeks of gestation, while those delivering 34–36 weeks of gestation are considered to 
have ‘late’ PTB. Although these designations are somewhat arbitrary, grouping women into 
PTB delivery epochs may help facilitate research and clinical prevention strategies.
Indeed, women presenting with symptoms of preterm labor prior to 34 weeks have been 
treated more aggressively with corticosteroids and tocolysis, whereas those with the same 
symptoms after 34 weeks generally have not received these interventions. Additionally, 
previous research has suggested that the etiologies of PTB likely vary by gestational age, 
with those of later PTB being much more heterogeneous.10,11 Indeed, infants delivered at 
the earliest gestational ages are at highest risk for adverse outcomes during the neonatal 
period and beyond, as effects of prematurity may persist through childhood and 
adolescence.7,12,13 In contrast, although infants delivered 34–36 weeks of gestation 
comprise the largest subset of preterm babies (~75%), they generally have a more benign 
course compared to their early preterm counterparts. However, late preterm infants continue 
to have an increased frequency of both immediate and long-term morbidity and mortality 
compared with term neonates.14–17 Limited evidence-based interventions to improve 
outcomes in the late preterm cohort exist, although studies are underway to assess efficacy 
of treatments traditionally reserved for earlier neonates (e.g., antenatal corticosteroid 
administration). Delineation of neonatal outcomes by delivery gestational age is needed to 
further clarify the continuum of mortality and morbidity frequencies among preterm 
neonates.
Thus, this study was designed to describe the contemporary frequencies of neonatal death, 
major and minor neonatal morbidity, and neonatal length of hospital stay across the 
spectrum of preterm gestational ages (23 – 36 weeks of gestation) in singletons. We also 
sought to describe cause of neonatal death across different preterm gestational ages.
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 Materials and Methods
This is a secondary analysis of the previously described NICHD Maternal-Fetal Medicine 
Units (MFMU) Network Assessment of Perinatal Excellence (APEX) obstetric cohort.18,19 
Briefly, the APEX study was an observational study designed to assist in the development of 
quality measures for intrapartum obstetric care. Patients eligible for data collection were 
those who were at least 23 weeks of gestation, had a live fetus on admission and delivered 
during the 24-hour period of randomly selected days representing one-third of deliveries at 
25 hospitals nationwide between 2008–2011; the main study included 115,502 women. 
Infants were followed until discharge or 120 days of age, whichever came first. Institutional 
review board (IRB) approval was obtained at each participating institution under a waiver of 
informed consent. This secondary analysis was reviewed by the University of Utah IRB and 
deemed exempt.
For the purposes of this secondary analysis, we included all liveborn, non-anomalous 
singleton neonates delivered 23–36 weeks of gestation. Gestational age was determined by 
best obstetrical estimate available at the time of admission. Women with inadequate 
pregnancy dating [e.g., pregnancies dated by last menstrual period only (without ultrasound 
confirmation) or by third trimester ultrasound only] were excluded. Neonates who were not 
resuscitated and died in the delivery room were excluded (i.e., only neonates offered a trial 
of life were included).
The primary outcomes were neonatal death, major neonatal morbidity (intraventricular 
hemorrhage grade III or IV, seizures, hypoxic ischemic encephalopathy, necrotizing 
enterocolitis stage II or III, bronchopulmonary dysplasia, or persistent pulmonary 
hypertension) and minor neonatal morbidity (hypotension requiring treatment, 
intraventricular hemorrhage grade I or II, necrotizing enterocolitis stage I, respiratory 
distress syndrome, and/or hyperbilirubinemia requiring treatment) during the initial 
hospitalization. Each neonate was categorized into the most severe category they met criteria 
for (death, major, or minor morbidity). Those without any of the aforementioned morbidities 
were considered to have no neonatal morbidity.
We also examined presumed cause of death among neonates who died during the initial 
hospitalization. Research staff reported the cause or causes of death for each neonate as 
applicable if available in the neonate’s chart. We grouped suspected causes of death into 
general classifications for the purposes of analysis. In some instances, more than one cause 
of death was included for each neonate. For example, we considered sepsis, pneumonia, and 
cytomegalovirus infections together as an ‘infectious’ etiology. The causes of death listed for 
each neonate were limited to what was listed by research staff under ‘cause of death.’ If an 
infant was also noted to have one or more serious comorbidities (e.g., hypoxic ischemic 
encephalopathy), these morbidities were not included in our cause(s) of death classification 
if they had not been listed as a ‘cause of death’. Neonates with ‘prematurity’ listed as the 
sole cause of death were considered to have no identifiable cause of death. Suspected causes 
of death were examined by gestational age at delivery, with babies grouped into 2 week 
epochs due to small numbers.
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The primary outcome frequencies of neonatal death, major neonatal morbidity, and minor 
neonatal morbidity, were calculated for each completed week of gestation from 23–36 weeks 
of gestation. Median length of hospital stay and postmenstrual age at discharge among 
survivors were also calculated. Tests for trend across each completed week of gestation were 
performed using the Cochran-Armitage trend test for categorical variables and Jonckheere-
Terpstra test for continuous variables. All tests were two-tailed; P<0.05 was used to define 
statistical significance. There was no adjustment for multiple comparisons and no imputation 
for missing data was performed. Data were analyzed using SAS software (SAS Institute, 
Cary, NC).
 Results
From the original APEX cohort of 115,502 deliveries, 8,334 women and their neonates met 
inclusion criteria for this analysis (Figure 1). Overall, 13% of women were transferred from 
another hospital. Baseline and demographic characteristics of the study population are 
shown in Table 1, stratified by delivery gestational age. In general, babies born at the earliest 
gestational ages were delivered by mothers who were more likely to be nulliparous and non-
Hispanic Black, and less likely to have received prenatal care (Table 1).
Labor and delivery outcomes and management characteristics are shown in Table 2. Preterm, 
premature rupture of membranes (PPROM) was common in this cohort, affecting 34.4% of 
pregnancies overall. Breech presentation, chorioamnionitis, cervical cerclage, and abruption 
were more common at the earliest delivery gestational ages, while placenta previa was more 
common among those delivered at later preterm gestational ages (Table 2). Exposure to 
antenatal corticosteroids was high overall, ranging from 77.5–93.4% for babies delivered at 
24–33 weeks of gestation. Data regarding antenatal magnesium sulfate administration for the 
purposes of fetal neuroprotection was not initially collected at the start of the study; this 
variable was added partway through the study, and as a result, data are missing on 57% of 
the cohort. Among those with data available, use ranged from a peak of 54.2% at 25 weeks 
gestation to a low of 0.7% at 36 weeks gestation.
There were 119 neonatal deaths (1.4%). Major morbidity was observed in 657 (7.9%) 
neonates, 3,136 (37.6%) had minor morbidity, and 4,422 (53.1%) survived without any of 
the studied morbidities.
Deaths declined rapidly with each advancing week of gestation (Table 3). Suspected cause(s) 
of death for the 119 neonates are listed in Table 4. Those delivered at the earliest gestational 
ages (23–24 weeks) were most likely to have none of the specific listed causes of death. 
There were 5 deaths among neonates delivered 31–33 weeks of gestation and no deaths 
among neonates delivered 34–36 weeks of gestation.
The decline in death was accompanied by an increase in major neonatal morbidity, which 
peaked at 54.8% at 25 weeks of gestation (Table 3). Individual contributors to the diagnosis 
of major morbidity and other outcomes among infants with major morbidity are shown in 
Supplementary Table A. Notably, despite advancing gestational age, severe neurologic injury 
(hypoxic-ischemic encephalopathy) was consistently a significant contributor to the 
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composite major morbidity across preterm delivery gestational ages. As frequencies of death 
and major neonatal morbidity fell, minor neonatal morbidity increased, peaking at 81.7% at 
31 weeks of gestation (Table 3). Beyond 32 weeks, the frequency of minor morbidity fell 
with each advancing week of gestation, and frequencies of major morbidity and death also 
continued to fall. Individual contributors to the diagnosis of minor morbidity and other 
outcomes among infants with minor morbidity are shown in Supplementary Table B.
At the earliest gestational ages (until 25 weeks of gestation), the median length of neonatal 
hospital stay increased each week (compared with the previous week) due to the large 
number of early deaths among neonates delivered at the youngest gestational ages (Table 5). 
After 25 weeks, the length of stay decreased significantly with each additional completed 
week of pregnancy. Among babies delivered from 26 to 32 weeks of gestation, each 
additional week in utero reduced the subsequent length of neonatal hospitalization by a 
minimum of 8 days (Table 5). Finally, among surviving neonates, we examined the median 
post-menstrual age at discharge from the hospital. The median post-menstrual age at 
discharge decreased progressively with each additional week in utero until a nadir around 36 
weeks post-menstrual age was noted for babies born between 31–35 weeks of gestation 
(Table 5).
We did not observe any temporal trends in neonatal death (p=.95 for trend) or major 
neonatal morbidity (p=.98 for trend) over the 3 year study period. There was a small 
decrease in the frequency of minor neonatal morbidity from study year 1 (39.6%) to year 3 
(36.4%), p=.02 for trend.
 Comment
Our data provide valuable information regarding a spectrum of neonatal outcomes for each 
week of completed pregnancy. This information may be useful when counseling patients 
regarding expected outcomes. Knowledge of risk and cause of death also may be useful for 
patient counseling. Clinical judgments have been shown, on average, to estimate lower 
survival probabilities than those supported by data.20,21 It has been observed that 
neonatologists with the correct estimation of neonatal survival intervene more often with 
appropriate invasive therapies, including mechanical ventilation, cardiopulmonary 
resuscitation, inotropes, and intravenous fluids, compared with clinicians who are not well 
informed regarding survival probabilities.22
The majority of prior studies examining delivery gestational age week-specific outcomes are 
not population based and many include cohorts that are now at least 5-10 years old, even if 
publication dates are more recent.23–25 Although this study includes a proportion of women 
who were transferred to academically affiliated centers for delivery at each gestational age, 
the study encompasses a wide range of social, demographic, and geographic diversity across 
the United States. Given the recent advances in maternal medicine (e.g., use of antenatal 
magnesium sulfate for neuroprotection), and neonatal medicine (e.g., shift from intubation 
and ventilator use towards continuous positive airway pressure oxygenation), mortality and 
morbidity may be overestimated in older studies, but it is difficult to truly ascertain when 
older studies are outdated. Stoll and colleagues recently found temporal changes in 
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individual preterm morbidities in neonates delivered at each preterm gestational age between 
2005–2012.6 Other more recent data focus on delivery gestational age epochs (e.g., very 
preterm, late preterm) and often do not provide week-specific gestational age outcomes. 
Although abundant, many studies of ‘late–preterm’ neonates have focused on mortality and 
morbidity differences between late-preterm and term infants. The presence of newer data 
does not invalidate older data per se, but as additional contemporary data incorporating 
modern management strategies is published, it adds to the body of evidence that can be used 
to counsel women and families regarding outcomes following PTB.
Our results were comparable to 8,877 neonates delivered 22–28 weeks of gestation between 
2008–2012 and included in a recent Neonatal Research Network publication.6 The incidence 
of death in our cohort was lower to the incidence of death at each of the delivery gestational 
ages examined in the Neonatal Research Network data (44 vs. 68% at 23 weeks, 32 vs. 38% 
at 24 weeks, 12 vs. 23% at 25 weeks, 11 vs. 15% at 26 weeks, 8 vs. 10% at 27 weeks, 2 vs. 
6% at 28 weeks), although the Neonatal Research Network included those with congenital 
anomalies which may account for some of the observed differences.6 We were unable to 
directly compare the incidence of major neonatal morbidity between cohorts given differing 
definitions of this composite outcome between studies, although trends were similar. In 
contrast to the Neonatal Network paper, we included neonates born at later gestational ages 
(through 36 weeks of gestation), and our focus was not on temporal trends in neonatal care 
or outcomes, but rather, more detailed obstetric and antenatal characteristics and the impact 
of such factors across the spectrum of preterm gestational ages. It is not unexpected that as 
the incidence of death and major morbidity fell, the incidence of minor morbidity rose, given 
our study design (neonates were classified by the worst outcome they met criteria for).
The cause of death among premature neonates is difficult to discern, and many neonates had 
no listed cause other than ‘extreme prematurity.’ Given that this is a study of preterm 
neonates, we chose not to report ‘extreme prematurity’ as a cause of death in our results 
since prematurity is a non-specific cause of death and arguably this was a contributing factor 
to all morbid outcomes in our study population of premature neonates. At the earliest 
gestational ages, variation in the use of active resuscitative treatment may have influenced 
some of the outcomes, as others have reported.26
It is notable that the frequency of delivery by cesarean among this cohort of pre-term 
neonates was high. At early gestational ages (24–31 weeks), between 58.3–67.9% of babies 
were delivered by cesarean; this may be partly explained by the high proportion of 
malpresentation (e.g., breech) among these very preterm neonates (21.8–55.7% were non-
vertex at 24–31 weeks, Table 2). However, even when the proportion of neonates in the 
vertex presentation increased to 84% or greater at 32 weeks, the frequency of cesarean 
delivery remained high, as 37.9% of 36 week neonates were delivered by cesarean. 
Historically in the US, rates of cesarean delivery of non-anomalous singleton preterm 
neonates have varied widely (from 4.1% to 62%); unfortunately, differing patient 
populations and inclusion criteria limits comparisons between studies.6,27–29
The traditional counseling provided to women delivering prematurely is that they can expect 
their baby to be discharged ‘around the time of their due date’. This counseling held true in 
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this cohort only for those babies delivered at the earliest gestational ages (23–26 weeks of 
gestation). Our findings at these early gestational ages were similar to the Neonatal Research 
Network Study reported by Stoll and colleagues.6 Surviving babies delivered at 27 weeks 
were discharged at a median 2.5 weeks prior to the maternal due date, whereas those 
delivered 31–35 weeks of gestation were discharged approximately 4 weeks prior to the 
maternal due date. The median post-menstrual age at discharge was noted to decrease with 
each additional week in utero, until it reached a nadir at 35.7 weeks of gestation for those 
delivered 32–33 weeks of gestation. Additionally, although significant advances have been 
made in perinatal and neonatal medicine, we found that babies born between 26 and 32 
weeks of gestation spend 8–11 days longer in the hospital compared with those premature 
neonates remaining in utero for one additional week.
Our study had several strengths. Although all delivered at academically-affiliated hospitals, 
these data include neonates delivered at centers with significant heterogeneity regarding 
location, geographic region, hospital level of care, and patient socioeconomic status. 
Additionally, the inclusion criteria were broad, and the analysis did not exclude neonates 
delivered for a particular condition or indication. In contrast to other large multi-center 
studies examining neonatal outcomes, we included detailed antenatal and pregnancy 
characteristics. Thus, these results are widely applicable within the United States. This large 
dataset has the additional unique quality of being collected prospectively by trained research 
staff, ensuring high quality data. The presentation of week-specific outcome data provides 
concrete data with regards to anticipated outcomes and neonatal length of hospitalization 
when counseling patients.
Our study should be interpreted with limitations in mind. As described above, the underlying 
etiology of neonatal death was difficult to determine in many cases. This limitation is not 
unique to our study. Even with prospective data collection, the cause of death is often 
multifactorial and subjective. As with any secondary analysis, we were limited by data 
collected at the time of the original study; for example, we do not have information 
regarding pre-pregnancy BMI, and we do not have data regarding stillbirths or long-term 
morbidities. Generalizability may be limited to academic-affiliated medical centers.
In conclusion, we have presented contemporary neonatal outcome data across the spectrum 
of viable preterm gestational ages. These data suggest that the designations of ‘early 
preterm’ and ‘late preterm’ are somewhat artificial and arbitrary. Our data show that there is 
a continuum of outcomes, with each additional week for gestation conferring survival 
benefit while reducing the length of initial hospitalization.
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Figure 1. 
Study inclusion.
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